Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04445285 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
A Phase 2 study of COVID-19, sponsored by Jon Simmons.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT04445285: Recruiting Phase 2 study of COVID-19, sponsored by Jon Simmons.
NCT04445285 is a Phase 2 study of COVID-19 that is actively recruiting participants, run by Jon Simmons. The registered enrollment target is 44 participants, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04445285, a Phase 2 study of COVID-19, is actively recruiting participants, sponsored by Jon Simmons.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
This Phase 2 Randomized Placebo Controlled Trial will determine if administering nebulized Dornase Alpha (rhDNase) to COVID-19 patients with respiratory failure is safe and will reduce 28-day mortality.
Primary Outcome
All Cause Mortality at 28 days
Conditions Studied
Interventions
- DRUG Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)
- DRUG 0.9%sodium chloride
Study Locations (1)
Alabama
- University of South Alabama - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2020-04-28 |
| Est. Completion | 2022-02-28 |
| Phase | Phase 2 |
What NCT04445285 shows while recruiting
NCT04445285 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) is the first listed.
NCT04445285 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT04445285 about?
NCT04445285 is a clinical study titled "Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure". This Phase 2 Randomized Placebo Controlled Trial will determine if administering nebulized Dornase Alpha (rhDNase) to COVID-19 patients with respiratory failure is safe and will reduce 28-day mortality.
What is the current status of trial NCT04445285?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2020-04-28. Estimated completion is 2022-02-28.
What conditions does trial NCT04445285 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT04445285?
The interventions under investigation include: Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) (DRUG), 0.9%sodium chloride (DRUG).
Who is sponsoring clinical trial NCT04445285?
This trial is sponsored by Jon Simmons, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04445285 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04445285's enrollment target sits among peer trials
44 255th of 298 higher than 44 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI